Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health (NASDAQ:JAGX) announced that its Board of Directors has unanimously authorized the inclusion of cryptocurrency as a treasury reserve asset. The company views this as a strategic move to diversify its treasury holdings with digital assets that offer potential upside and inflation protection.

CEO Lisa Conte revealed that several banks and an investor have approached Jaguar with cryptocurrency transaction terms. The company is currently evaluating the potential benefits for shareholders and its core development programs. Jaguar continues to focus on developing crofelemer, its plant-based prescription medicine, across three main programs: intestinal failure, cancer therapy-related diarrhea treatment, and expanding Canalevia® for dogs.

Jaguar Health (NASDAQ:JAGX) announced plans to pursue European Medicines Agency approval for Canalevia to treat general diarrhea in dogs in the EU. The drug, which contains plant-based crofelemer, is currently conditionally FDA-approved for chemotherapy-induced diarrhea in dogs under the name Canalevia-CA1.

The company is in discussions with potential animal health partners to achieve three goals: EU approval for general diarrhea treatment, maintaining U.S. availability for chemotherapy-induced diarrhea, and expanding U.S. indication to include general diarrhea. A completed study of 200 dogs showed significant improvement in fecal scores using a revised endpoint analysis. The potential market is substantial, with 104 million dogs in Europe and approximately 6 million annual cases of acute and chronic diarrhea in U.S. veterinary practices.

Jaguar Health (NASDAQ:JAGX) has announced the extension of maturity date for its convertible promissory notes from June 30, 2025 to January 30, 2026. The extension applies to approximately $2.57 million in aggregate principal amount from the original $3.448 million bridge financing that closed on March 31, 2025. Prior to this extension, five investors converted $0.866 million (including accrued interest) into company equity.

The bridge financing participants include the company's CEO, board members, other C-suite executives, and institutional and accredited investors. The funding aims to support Jaguar's three core development programs for crofelemer: orphan disease intestinal failure program, cancer therapy-related diarrhea treatment, and expansion of Canalevia® for dogs.

Jaguar Health (NASDAQ:JAGX) reports progress in its orphan disease intestinal failure program for crofelemer. The Phase 2 study for microvillus inclusion disease (MVID) in pediatric patients has reached 25% enrollment, while the SBS-IF study in adults is above 10%. Initial proof-of-concept results show crofelemer reduced total parenteral nutrition requirements by up to 27% in MVID patients and 12.5% in short bowel syndrome patients. The company expects to complete its randomized Phase 2 MVID study by mid-2026. Jaguar is actively seeking business development partnerships for licensing rights to develop and commercialize its intestinal failure products, aiming to generate non-dilutive funding. The positive early results could potentially support inclusion in EMA's PRIME program and FDA's Breakthrough Therapy program, potentially accelerating regulatory approval pathways.

Jaguar Health (NASDAQ:JAGX) announced that its founder, president and CEO Lisa Conte will deliver a virtual presentation at the Emerging Growth Conference on June 18, 2025, from 9:40 - 10:10 AM Eastern Time. The presentation will be available online, with a replay accessible through EmergingGrowth.com and the Emerging Growth YouTube Channel. This conference presentation aims to provide updates on near-term catalysts for the company.

Jaguar Health (NASDAQ:JAGX) has established the first study site for its field study of Canalevia-CA1, an FDA conditionally approved prescription drug for treating chemotherapy-induced diarrhea (CID) in dogs. The company has two main objectives: obtaining full FDA approval for CID treatment and expanding the drug's indication to treat general, non-infectious diarrhea in dogs. Jaguar is actively seeking partners to fund development and commercialization of the drug for the broader diarrhea indication. The market opportunity is significant, with approximately 6 million annual cases of acute and chronic diarrhea in dogs seen by U.S. veterinarians. The prospective, randomized, open-label field study will collect real-world data on Canalevia-CA1's effectiveness in dogs undergoing chemotherapy. Currently, there are no FDA-approved drugs for treating general diarrhea in dogs, despite it being one of the most common reasons for veterinary visits.

Jaguar Health (NASDAQ:JAGX) announces a virtual fireside chat featuring CEO Lisa Conte on June 10, 2025, at 9:00 AM ET as part of Lytham Partners' Spring 2025 Spotlight Series. The discussion will center on the company's recent FDA meeting regarding statistically significant responder analysis results from their Phase 3 OnTarget trial's breast cancer patient subgroup. The company notes that the US metastatic breast cancer population potentially qualifies as an orphan population, aligning with their core focus. Jaguar Health plans to pursue authorization for an expanded access program for breast cancer patients who may not qualify for a potential pivotal treatment trial with crofelemer in metastatic breast cancer patients.

Jaguar Health (NASDAQ:JAGX) reports a productive Type C Meeting with the FDA regarding crofelemer for cancer therapy-related diarrhea (CTD) in metastatic breast cancer patients. The company proposed two pathways: conducting a pivotal treatment trial and initiating an expanded access program. While the Phase 3 OnTarget trial didn't meet its primary endpoint overall, the breast cancer patient subgroup (183 of 287 participants) showed statistically significant improvement in diarrhea response compared to placebo. The company plans to pursue orphan drug designation, as the US metastatic breast cancer population qualifies as an orphan population. Jaguar also intends to seek Breakthrough Therapy and/or Fast Track designation. Crofelemer has been previously commercialized for HIV-related diarrhea since 2012 with no reported serious adverse events.

Jaguar Health (NASDAQ:JAGX) has announced that its founder, president and CEO Lisa Conte will participate in a virtual fireside chat on June 10, 2025, at 9:00 AM Eastern. The event is part of Lytham Partners' Spring 2025 Spotlight Series and will focus on the company's efforts to advance its orphan disease development programs. The one-hour virtual discussion will be available for replay after the event for those unable to attend the live session.